Comprehensive Psychiatry
Volume 41, Issue 4 , Pages 229-236, July 2000

Personality disorders and traits in patients with body dysmorphic disorder

From Butler Hospital and the Department of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, RI; and the Biological Psychiatry Program, University of Cincinnati School of Medicine, Cincinnati, OH.

Abstract 

Individuals with body dysmorphic disorder (BDD) have been postulated to have schizoid, narcissistic, and obsessional personality traits and to be sensitive, introverted, perfectionistic, and insecure. However, data on personality traits and disorders in BDD are limited. This study assessed 148 subjects with BDD, 26 of whom participated in a fluvoxamine treatment study; 74 subjects were assessed for personality disorders with the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II), 100 subjects completed the NEO-Five Factor Inventory (NEO-FFI), and 51 subjects completed the Rathus Assertiveness Scale. Forty-two subjects (57%) had one or more personality disorders, with avoidant personality disorder (43%) being most common, followed by dependent (15%), obsessive-compulsive (14%), and paranoid (14%) personality disorders. On the NEO-FFI, the mean scores were in the very high range for neuroticism, the low range for extraversion and conscientiousness, the low-average range for agreeableness, and the average range for openness to experience. On the Rathus Assertiveness Scale, the mean score was −17.1 ± 32.0 for women and −17.0 ± 32.3 for men. Among fluvoxamine responders, the number of personality disorders significantly decreased between the study baseline and endpoint. These findings suggest that the rate of personality disorders in BDD is relatively high, with avoidant personality disorder being most common. The high neuroticism scores and low extraversion scores are consistent with this finding.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by National Institute of Mental Health Grant No. R-29 MH54841 (K.A.P.) and an unrestricted educational grant from Solvay Pharmaceuticals and Pharmacia and Upjohn (K.A.P. and S.L.M.).

PII: S0010-440X(00)98069-6

doi:10.1053/comp.2000.7429

Comprehensive Psychiatry
Volume 41, Issue 4 , Pages 229-236, July 2000